This final analysis of FIGHT-202 demonstrated continued durable response, prolonged OS, and manageable AEs in patients with previously treated advanced or metastatic CCA with FGFR2 fusions or rearrangements, further supporting regulatory approvals of pemigatinib based on this single-arm, phase II study.28 The gene discussed is FGFR2; the disease is cholangiocarcinoma.